Background {#Sec1}
==========

Bleedings are a common complication of percutaneous coronary interventions (PCI) both affecting the arterial access site and occurring in terms of general outcome. Bleedings do not only affect patients' satisfaction, but do also increase mortality \[[@CR1]\]. With specific regard to femoral arterial access-site bleedings, different strategies have been evaluated in order to reduce them. Besides manual compression and application of pressure bandages around the hips, so called vascular closure devices (VCD) were developed in the early 1990's \[[@CR2]\]. VCD were shown to reduce access-site bleedings and to reduce post interventional time to hemostasis \[[@CR3], [@CR4]\]. In contrast non-access site bleedings are supposed to result in a higher mortality risk compared to bleedings from primary access site \[[@CR5]\]. Vavalle et al. showed in-hospital bleedings in acute coronary syndrome (ACS) patients to be associated with an increased risk of death, whereas mild access-site bleedings were not \[[@CR6]\].

VCD have entered the medial practice in modern cardiac catheterization laboratories \[[@CR3], [@CR7]\]. Additionally this treatment has proven advantageous on the patients' overall satisfaction and mobilization \[[@CR8]\]. Different characteristics were shown to predict arterial access-site complications after PCI, such as advanced age, female sex, bleeding predispositions or renal failure \[[@CR9], [@CR10]\]. However, there is no evidence currently available on how the height of femoral arterial puncture alters the occurrence of PCI-related bleedings.

Therefore, this sub-study of the FERARI trial \[[@CR11], [@CR12]\] aims to evaluate the differences of PCI-related bleedings depending on the height of femoral arterial puncture in combination with the treatment of a VCD.

Methods {#Sec2}
=======

Study patients and data collection {#Sec3}
----------------------------------

The present study is based on a subset of patients from the "Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI)" study. The FERARI study is a single-center prospective, nonrandomized observational study being performed at the First Department of Medicine, University Medical Centre Mannheim (UMM) in Mannheim, Germany (clinicaltrials.gov identifier: NCT02455661). The study was approved by the medical ethics commission II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany. Written informed consent is obtained from all participating patients or their legal representatives \[[@CR11]\]. Briefly, those patients with a valuable inguinal angiography before successful implantation of the AngioSealTM femoral VCD (Angio-Seal™; St. Jude Medical, Inc., St Paul, USA) following PCI were included. Patients with radial PCI and patients with a femoral PCI without any or a valuable inguinal angiography were excluded (Fig. [1](#Fig1){ref-type="fig"}). Performing femoral angiography belonged to the operators' discretion and was performed to verify the location of puncture above or below the epigastric artery, to detect severe calcification of the puncture site or to alleviate difficult femoral or aortic passing.Fig. 1Flow chart illustrating the selection of patients for the present sub-analysis of the FERARI study

Standardized angiography was performed from left anterior oblique (LAO) 30° and right anterior oblique (RAO) 30° view. A valuable inguinal angiography was defined, when the entire inguinal anatomy of the iliac and femoral arteries was documented, including the femoral bifurcation. All angiographies were systematically reviewed on the "OsiriX Imaging Software" (Pixmeo SARL, Switzerland) by two independent cardiologists in order to determine the correct height of femoral arterial puncture.

Femoral arterial puncture was performed by standardized Seldinger technique in all patients using a conventional stainless steel puncture needle (SFM Medical Devices©, Wächtersbach, Germany) (i.e. no micropuncture needle). Ultrasound guiding during arterial puncture or concomitant ipsilateral venous or arterial access was excluded. Number of needle passes was not documented, but was restricted to a maximum number of 5 in cases of difficult anatomy or calcification. The allowed French size in the FERARI study was 5--6 French. Only four different experienced interventional cardiologists performed PCIs in this study with a minimum volume of 300 PCI cases per year and an equal distribution of experiences with both the radial and femoral approach of each operator. Operators had already implanted at least 100 AngioSeal© femoral closure devices per year. All operators were equally experienced in both radial and femoral accessed interventions \[[@CR11]\].

Definition of height of femoral arterial puncture based on anatomical description {#Sec4}
---------------------------------------------------------------------------------

The procedural X-ray contrast angiography of the femoral arteries was reviewed systematically and the access point was described anatomically. Arterial parts were classified into the external iliac artery (EIA), common femoral artery (CFA), femoral bifurcation, profound femoral artery (PFA) and superficial femoral artery (SFA). Based on these anatomic landmarks 4 different puncture heights were defined: high puncture at the EIA and above the inguinal ligament, femoral puncture at the CFA, femoral bifurcation and low puncture below the femoral bifurcation either at the PFA or SFA.

The border between EIA and CFA was drawn at the superficial epigastric artery as an indicator for the localization of the inguinal ligament. The femoral bifurcation was described as the area of 1 cm into each proximal and distal vessel branches. The PFA and SFA were distinguished by the typical lateral projection of the prominently visual course of the PFA and its side branches, namely the lateral circumflex femoral artery and the medial circumflex femoral artery.

Post interventional procedure {#Sec5}
-----------------------------

After successful PCI the VCD was implanted. Afterwards a circumferential pressure bandage is added to the puncture site to further support the prevention of bleedings. Patients were advised to remain in lying position (i.e. bed-rest) for 6 h. Pressure bandages were removed after a total of 12 h, unless access site bleedings occurred. Patients were not subject to early ambulation. All PCI patients remained hospitalized for at least 24 h, early ambulation was not allowed after PCI.

Outcome definition and follow-up {#Sec6}
--------------------------------

All patients were followed up during hospital stay and until 30-days after the index procedure directly and by standardized telephone visits. The primary outcome was defined as overall, access-site and non-access-site bleedings occurring within 30-days of follow-up. Overall bleedings were defined according to established bleeding classifications, i.e. "Bleeding Academic Research Consortium" (BARC) score, "The Thrombolysis in Myocardial infarction" (TIMI) score and the "Global Use of Strategies to Open Occluded Arteries" (GUSTO) score \[[@CR6], [@CR13], [@CR14]\]. Access site bleedings were defined as hematomas, active bleedings, dissections, pseudoaneurysms, arteriovenous fistula, retroperitoneal hematoma and non-access-site bleeding. Access site bleedings were classified according to the study-specific FERARI classification, as described previously: \[[@CR11]\] small (\<5 cm), intermediate (5--15 cm), large (\>15 cm) hematomas and complicated access-site bleedings.

Statistics {#Sec7}
----------

Statistical analyses were performed with SPSS Statistics (IBM, Armonk, NY) and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Data are presented as medians with interquartile ranges (25th and 75th percentiles) or as total numbers with group-related percentages. Normal distribution of data was tested with the Kolmogorov-Smirnov test. In case of normal distribution, the *t*-test was applied to compare scaled data. Scaled variables not normally distributed were compared using the Mann--Whitney *U* test. Categorical variables were compared using the chi-squared test, in case of low event rates the Fisher's exact test was used. Risk factors for access site bleedings, which were shown to differ significantly between the two study groups, were adjusted using uni- and multivariate linear regression analyses for the predefined study outcomes representing the dependent variable. Level of significance was set at *p* \< 0.05 (two-tailed), a statistical trend was defined at *p* \< 0.1 (two-tailed).

Results {#Sec8}
=======

Study population {#Sec9}
----------------

As illustrated in Fig. [1](#Fig1){ref-type="fig"}, of the initial study cohort of 400 patients, final number of 95 patients revealed valuable inguinal angiography as well as successful femoral PCI with a femoral VCD and were included for the present sub-analysis.

Figure [2](#Fig2){ref-type="fig"}, illustrates the distribution of the different arterial puncture sites. CFA was the most punctured arterial site (41%), followed by the femoral bifurcation (39%) and low puncture distally to the femoral bifurcation either at the PFA or SFA (20%). High punctures above the inguinal ligament were not performed within the present cohort.Fig. 2Topographic scheme demonstrating the different heights of femoral arterial puncture as well as the distribution of puncture rates being evaluated from inguinal angiographies following PCI. Puncture rates are presented as n (%)

Patient demographics were equally distributed between groups (Table [1](#Tab1){ref-type="table"}), with a mean age of 67 to 71 years. Patients were often male, being mostly present in all subgroups (80% in common femoral, 64% in femoral bifurcation), despite in patients of the low puncture group (37%) (*p* = 0.006). Body mass index (BMI) was higher in femoral punctured patients compared to patients in the low puncture groups (*p* = 0.038). No further significant differences were found regarding cardiovascular risk factors between subgroups (Table [1](#Tab1){ref-type="table"}). Accordingly the indications for PCI as well as mean procedural length or implanted stent lengths did not differ significantly (Table [1](#Tab1){ref-type="table"}). The hospital stay time averaged at 9 days. During the 30 day follow-up period 11% of patients were rehospitalized, 4% received additional coronary angiography, while 3% received additional stent implantation. One stent thrombosis was documented, which resulted in the only death (1%).Table 1Baseline characteristics of the study populationAll patients (*n* = 95)Common femoral artery (*n* = 39)Femoral bifurcation (*n* = 37)Low puncture (*n* = 19)*p* valueAge, mean ± SD69.3 ± 10.567 ± 10.670.7 ± 9.771.4 ± 11.40.142BMI, mean ± SD28.3 ± 5.626.4 ± 3.729.5 ± 7.229.6 ± 4.90.038Male, n (%)61 (64)31 (80)23 (64)7 (37)0.006Cardiovascular risk factors, n (%) Arterial hypertension71 (75)26 (67)31 (86)14 (74)0.228 Diabetes34 (35)9 (23)16 (44)9 (47)0.089 Smoking16 (17)10 (26)3 (8)3 (16)0.118 Cardiac family history12 (13)3 (8)6 (16)3 (16)0.484Prior medical history, n (%) Congestive heart failure12 (13)5 (13)5 (14)2 (11)0.922 Coronary artery disease46 (48)16 (41)20 (54)10 (53)0.482 Peripheral artery disease6 (6)3 (8)2 (5)1 (5)1.000 Chronic kidney disease21 (22)5 (13)10 (27)6 (32)0.159Indication for PCI, n (%) STEMI6 (6)2 (5)2 (5)2 (11)0.741 NSTEMI27 (28)12 (31)11 (30)4 (21)0.726 Unstable AP19 (20)9 (24)6 (16)4 (21)0.748 Stable AP19 (20)6 (15)8 (21)5 (26)0.592 Other24 (25)10 (26)10 (27)4 (21)0.887 Procedural dataAverage Time47525150 Drug eluting stents, n (%)85 (90)35 (90)33 (89)17 (90)1.000 Bare metal stents, n (%)4 (4)1 (3)2 (5)1 (5)0.836 Total stent length, mean ± SD42.4 ± 29.739.5 ± 24.842.3 ± 31.748.3 ± 30.60.561

Table [2](#Tab2){ref-type="table"} summarizes the different anticoagulant therapies being administered for all spectated bleedings. Neither pre-, peri- nor post-interventional combinations of anticoagulant therapies revealed any significant differences related to the different groups of arterial puncture height.Table 2Anticoagulation of patients with recorded bleedings during PCIAll patients (*n* = 50)Common femoral artery (*n* = 24)Femoral bifurcation (*n* = 15)Low puncture (*n* = 11)*p* valuePre-PCI, n (%) ASS27 (54)11 (46)10 (67)6 (55)0.447 Clopiogrel9 (18)5 (21)1 (7)3 (27)0.346 Ticagrelor1 (2)0 (0)1 (7)0 (0)0.520 Prasugrel5 (10)1 (4)3 (20)1 (9)0.284 LMH2 (4)0 (0)1 (6)1 (9)0.265 NOAC/OAC8 (16)4 (17)3 (20)1 (9)0.886 None17 (34)11 (46)2 (13)4 (36)0.104 INR, mean ± SD1.07 ± 0.231.09 ± 0.261 ± 0.081.16 ± 0.330.066Peri-PCI, n (%) Heparin50 (100)24 (100)15 (100)11 (100)1 GP IIB/IIIA inhibitor2 (4)1 (4)0 (0)1 (9)0.481 Bivalirudin1 (2)0 (0)1 (7)0 (0)0.520Post-PCI, n (%) ASS + Clopidogrel33 (66)14 (58)10 (67)9 (82)0.395 ASS + Ticagrelor4 (8)1 (4)2 (13)1 (9)0.545 ASS + Presugrel6 (12)5 (21)1 (7)0 (0)0.279 ASS + NOAC/OAC0 (0)0 (0)0 (0)0 (0)- Thienopyridine + NOAC/OAC3 (6)1 (4)2 (13)0 (0)0.432 Triple Therapy4 (8)3 (13)0 (0)1 (9)0.424*LMH* low molecular heparin, *NOAC/OAC* Warfarin or one of the new oral anticoagulants (Rivaroxaban, Dabigatran, Apixaban); Triple therapy: ASS + Clopidogrel + NOAC/OAC

Bleedings related to the height of femoral arterial puncture {#Sec10}
------------------------------------------------------------

Overall bleedings occurred in more than half of all patients (53%) with prior femoral angiography, which was not significantly different compared to patients without femoral angiography (n = 105, overall bleeding rate 58%) (*p* = 0.437) (Table [3](#Tab3){ref-type="table"}). Most patients received 6 F introducer sheaths (femoral angiography: 85% versus 15%; no femoral angiography: 95% versus 5%). No differences of bleeding rates were found depending on the choice of sheath size or presence of angiography (*p* \> 0.05).Table 3Bleeding rates depending on the presence of femoral angiography in PCI patients with a femoral VCDAngiography (*n* = 95)No angiography (*n* = 105)*p* valueOverall bleedings, n (%)50 (53)61 (58)0.437 Related to 5 F, ratio (%)6/14 (43)7/15 (47)0.837 Related to 6 F, ratio (%)44/81 (54)54/90 (60)0.453BARC, n (%) 045 (48)44 (42)0.437 138 (40)50 (48)0.278 210 (11)10 (10)0.813 3A0 (0)1 (1)1 3B2 (2)0 (0)0.224 3C0 (0)0 (0)- 40 (0)0 (0)- 50 (0)0 (0)-TIMI, n (%) 045 (47)44 (42)0.437 150 (53)60 (57)0.522 20 (0)1 (1)1 30 (0)0 (0)-GUSTO, n (%) 045 (47)44 (42)0.437 149 (52)60 (57)0 20 (0)1 (1)1 31 (1)0 (0)0.475FERARI, n (%) 045 (47)44 (42)0.437 125 (26)27 (26)0.923 213 (14)10 (10)0.681 39 (10)11 (10)0.813 43 (3)3 (3)1

With regard to BARC, TIMI and GUSTO bleeding classifications 52.6% patients received a score of 1 or higher (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Moderate bleedings (GUSTO 2) did not develop, whereas a severe bleeding (GUSTO 3) was only observed once (1.1%) in the common femoral subgroup. Including all primary access site bleedings, 61.5% femoral punctured patients showed bleedings (BARC, TIMI, GUSTO score ≥ 1). In the femoral bifurcation group bleedings were spectated in 41% patients, low puncture showed 58% bleedings (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Mostly observed bleedings consisted of local hematomas (FERARI class 1--3) in 49.5% patients. Complicated access-site bleedings consisted of post-interventional open bleedings (2.1%), AV-dissection (2.1%), aneurysm spurium (1.1%).Table 4Bleedings according to heights of femoral arterial puncturesCommon femoral artery (*n* = 39)Femoral bifurcation (*n* = 37)Low puncture (*n* = 19)*p* valueOverall bleedings, n (%)24 (62)15 (41)11 (58)0.163 Related to 5 F, ratio (%)2/3 (67)2/8 (25)3/3 (100)0.143 Related to 6 F, ratio (%)22/36 (61)13/29 (45)8/16 (50)0.409BARC, n (%) 015 (38)22 (60)8 (42)0.163 116 (41)13 (35)9 (47)0.667 27 (18)2 (5)1 (5)0.191 3A0 (0)0 (0)0 (0)- 3B1 (3)0 (0)1 (5)0.677 3C0 (0)0 (0)0 (0)- 40 (0)0 (0)0 (0)- 50 (0)0 (0)0 (0)-TIMI, n (%) 015 (38)22 (59)8 (42)0.163 124 (62)15 (41)11 (58)0.163 20 (0)0 (0)0 (0)- 30 (0)0 (0)0 (0)-GUSTO, n (%)2 (5)2 (5)2 (11)0.741 015 (39)22 (60)8 (42)0.163 123 (59)15 (41)11 (58)0.228 20 (0)0 (0)0 (0)- 31 (3)0 (0)0 (0)1.000FERARI, n (%) 015 (38)22 (60)8 (42)0.163 112 (31)8 (22)5 (26)0.663 26 (15)6 (16)1 (5)0.487 35 (13)1 (3)3 (16)0.143 41 (3)0 (0)2 (11)0.101

Discussion {#Sec11}
==========

The present subanalysis of the FERARI study evaluates differences of PCI-related bleedings depending on the height of femoral arterial puncture in combination with the treatment of a femoral VCD. It was demonstrated that the common femoral artery and femoral bifurcation were the most punctured access sites in the present cohort possibly revealing easiest anatomical accessibility. Arterial punctures below the femoral bifurcation was less performed. Accordingly, arterial puncture at the bifurcation revealed a numerically lowest amount of bleedings (41%) compared to the CFA (62%) and lower punctures (58%), without reaching statistical cut-off.

In contrast, lower arterial punctures could not be shown to be associated with a worse outcome. It might me speculated whether a lower arterial puncture might be a valid alternative puncture site without increasingly risking bleedings.

No significant differences of baseline characteristics, indications of PCI and anticoagulation therapies were seen according to the described femoral arterial puncture sites, with the exception of a significantly higher number of female patients in the lower puncture group. This might indicate, that female patients are more likely to be punctured distally of the femoral bifurcation than male patients. Comparing female and male bleeding probabilities, no significance was recorded in the present study, although former studies have shown female gender having an increased bleeding risk \[[@CR9]\]. Therefore the high number of bleedings in the lower puncture group might partially be a result of the high percentage of female patients (63%). The BMI differences might indicate that increased weight moves the operator to perform arterial puncture more distally. Additionally overweight and obese patients have lower bleeding rates \[[@CR15]\].

The extend of documented bleedings was rarely of severe nature. Whether severe bleedings are associated similarly by different arterial puncture sites therefore needs to be investigated by large scale studies. The evaluation of anticoagulation therapies did not show any significant differences in each evaluated subgroup, making an uneven influence on the observed bleedings unlikely.

Study limitations {#Sec12}
-----------------

Patients were included retrospectively in the FERARI study after successful PCI and either VCD implantation or radial compression bracelet usage and therefore preselected and non-randomized. Only a single type of VCD was used in this study. Unsuccessful VCD implantations were not included into the FERARI study and could therefore not be analysed. Follow up period was limited to 30 days, which does not give any information on long term effects. Finally, bleeding events were only described clinically, without a standardized imaging technique such as duplex sonography.

Conclusions {#Sec13}
===========

In conclusion, the present study suggests, that bleeding risks associated with different punctured femoral arterial sites does not differ significantly. Therefore, neither CFA, femoral arterial bifurcation, nor profound and superficial femoral artery might have favoured the occurrence of bleeding. Weather the statistical trend being observed for a less bleeding rate at the femoral bifurcation is just statistical variance or due to a low study population needs to be investigated within a larger prospective studies.
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